LENSAR (NASDAQ:LNSR) Releases Earnings Results, Beats Expectations By $1.38 EPS

LENSAR (NASDAQ:LNSR) released its earnings results on Friday. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $0.18 by $1.38, reports. The firm had revenue of $13.43 million for the quarter, compared to analyst estimates of $13.40 million.

Here are the key takeaways from LENSAR’s conference call:

• LENSAR is independent again and rebuilding commercial momentum; management said distributor purchase orders were received post-quarter and international system shipments are expected this quarter, signaling early recovery of OUS placements.
• Recurring revenue strengthened — recurring revenue was $12.6 million, up 9% year-over-year and accounted for 94% of Q1 revenue, which management frames as a more durable business model.
• Headline net income was $36.3 million but was largely non-cash (warrant fair-value gain and a $10M acquisition deposit); adjusted EBITDA was negative $0.3M and cash on hand was $13.5M, highlighting limited near-term cash-generation and a reliance on operational recovery.
• Installed base and procedure trends show traction — 7 ALLY placements in Q1 (ALLY ~205 systems), total installed base ~440 (up 12% YoY), ~54,000 procedures in Q1, and U.S. market share of 23.4% with management expecting renewed share gains as placements resume.
• Product roadmap focused on expanding ALLY capabilities — management plans corneal applications, more robotic functions and automation of docking to extend technological leadership, but timing and commercial impact remain uncertain.

LENSAR Price Performance

LNSR stock traded up $0.41 during trading on Friday, hitting $5.64. 153,766 shares of the company traded hands, compared to its average volume of 73,927. The stock’s 50-day simple moving average is $7.39 and its 200 day simple moving average is $10.11. The company has a market cap of $68.24 million, a PE ratio of -1.94 and a beta of 0.84. LENSAR has a 1 year low of $5.06 and a 1 year high of $14.31.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LNSR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of LENSAR in a report on Tuesday, April 21st. BTIG Research raised LENSAR from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Tuesday, March 17th. Finally, Lake Street Capital raised LENSAR from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Wednesday, April 1st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Barclays PLC increased its position in shares of LENSAR by 10.3% in the fourth quarter. Barclays PLC now owns 14,857 shares of the company’s stock valued at $173,000 after buying an additional 1,389 shares in the last quarter. LPL Financial LLC increased its position in shares of LENSAR by 11.3% in the fourth quarter. LPL Financial LLC now owns 17,922 shares of the company’s stock valued at $208,000 after buying an additional 1,819 shares in the last quarter. Prelude Capital Management LLC purchased a new stake in shares of LENSAR in the third quarter valued at approximately $145,000. One68 Global Capital LLC purchased a new stake in shares of LENSAR in the third quarter valued at approximately $214,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in shares of LENSAR in the third quarter valued at approximately $125,000. 40.15% of the stock is currently owned by hedge funds and other institutional investors.

LENSAR Company Profile

LENSAR, Inc, headquartered in Orlando, Florida, is a medical technology company specializing in advanced laser systems for ophthalmic surgery. Its flagship product, the LENSAR Laser System, combines proprietary three-dimensional imaging with precision-guided femtosecond laser delivery to perform critical steps in cataract procedures, including capsulotomy creation, lens fragmentation and corneal incisions.

Founded in 2005, LENSAR has concentrated its research and development efforts on enhancing surgical accuracy and patient outcomes in cataract treatment.